Clinical trials · Texas
Recurrent Ovarian Carcinoma clinical trials in Texas
We’re tracking 36 recruiting recurrent ovarian carcinoma studies with a site in Texas — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Texas
- NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial tests an experimental drug called NKT3964 for people with certain advanced cancers that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Austin, TexasAges 19 years+ - NCT05564377RecruitingPhase 2
Find targeted cancer treatments using genetic testing
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
Abilene, TexasAges Any age - NCT05231122RecruitingPhase 2
Pembrolizumab and bevacizumab for recurrent ovarian cancer
This trial studies whether adding pembrolizumab to bevacizumab (and sometimes an anti-CD40 drug) can help control recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also looks at whether the treatment can shrink tumors and keep them from growing for longer.
Houston, TexasAges 18 years+ - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Houston, TexasAges 1–30 - NCT03968406RecruitingPhase 1
Talazoparib plus radiation for recurrent gynecologic cancers
This Phase 1 study tests whether the cancer drug talazoparib, combined with radiation, can better control recurrent gynecologic cancers in the pelvis/abdomen. It focuses on patients whose cancer has come back locally enough that radiation can be given, while other disease is not rapidly worsening.
Houston, TexasAges 18 years+ - NCT03564340RecruitingPhase 1/Phase 2
Testing ubamatamab alone or with cemiplimab for ovarian and MUC16+ cancers
This early-phase study tests ubamatamab, a cancer-targeting antibody, given by itself or with cemiplimab. It is meant to treat adults whose cancer has come back and who may not have other good standard options left.
Houston, TexasAges 18 years+ - NCT03604315RecruitingPhase 1
PET/CT scan testing a new radioactive tracer for tumors
This early-phase study uses PET/CT scans to see how well a new radioactive tracer (a tiny dose of a special material) highlights solid tumors in the body. It may help researchers learn whether this tracer can better find and track tumor spots seen on standard scans.
Houston, TexasAges 18 years+ - NCT06799065RecruitingPhase 1/Phase 2
Oral drug for advanced solid tumors including ovarian cancer
This trial tests a new daily pill that targets a protein helping cancer cells divide. It may stop tumors from growing in people with advanced or metastatic cancer that has returned or stopped responding to standard treatments, including some types of ovarian, lung, and other solid tumors.
Houston, TexasAges 18 years+ - NCT05039801RecruitingPhase 1
Study drug IACS-6274 tested for advanced solid tumors
This Phase 1 study tests the experimental drug IACS-6274, sometimes with bevacizumab and paclitaxel, in people with advanced solid tumors that have not responded to standard treatments. It aims to find the safest dose and to learn whether the treatment can shrink or control cancer for certain tumor mutation types.
Houston, TexasAges 18 years+ - NCT05059444Recruiting
Blood test to catch cancer early after treatment
This study looks for signs of cancer left in the body after treatment using a simple blood test (called a liquid biopsy). It aims to see if the test can catch cancer that might come back earlier than regular scans.
Edinburg, TexasAges 18 years+ - NCT06065462RecruitingPhase 1/Phase 2
Dostarlimab and LB-100 for clear cell ovarian cancer
This trial tests a combination of two drugs—dostarlimab (an immunotherapy) and LB-100 (a new drug targeting a protein called PP2A)—for people with clear cell ovarian cancer that has returned or is resistant to platinum chemotherapy. The goal is to see if this combination is safe and effective for this specific type of cancer.
Houston, TexasAges 18 years+ - NCT04196257RecruitingPhase 1
Early-dose trial of BP1001-A for advanced or recurrent solid tumors
This Phase 1 trial studies BP1001-A in people with advanced or recurring solid cancers to find a safe dose and learn how the treatment works. You may be asked for tumor biopsies before and possibly after treatment to see how the cancer responds.
Dallas, TexasAges 18 years+ - NCT07444814RecruitingPhase 1
HWK-007 for advanced solid tumors
This trial tests a new drug called HWK-007, which is designed to target and attack cancer cells while sparing healthy ones. It is for people with specific advanced solid tumors (lung, endometrial, or ovarian cancer) that have not responded well to standard treatments.
Houston, TexasAges 18 years+ - NCT06824467RecruitingPhase 3
Maintenance Therapy Study for Recurrent Ovarian Cancer
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
Austin, TexasAges 18 years+ - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Houston, TexasAges 18 years+ - NCT07807956RecruitingPhase 1
Intravenous study drug for advanced solid tumors
This trial tests an investigational drug given through an IV to see if it can help people with advanced solid tumors. It aims to learn about side effects, how the drug works in the body, and whether it can slow or shrink the cancer.
Irving, TexasAges 18 years+ - NCT05123482RecruitingPhase 1/Phase 2
Study of an experimental drug for advanced solid tumors
This trial tests a new drug, called AZD8205, alone or with other medicines, for people with advanced or metastatic solid tumors that have not responded to standard treatment. It aims to see if the drug can shrink tumors or slow their growth.
Houston, TexasAges 18 years+ - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Austin, TexasAges 18 years+ - NCT06840886RecruitingPhase 1
Study of PHST001 for advanced solid tumors
This trial tests an experimental drug called PHST001 for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if PHST001 can help shrink or control the tumor.
Fort Worth, TexasAges 18 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study of rinatabart sesutecan for advanced solid tumors
This trial tests an investigational drug called rinatabart sesutecan (also known as Rina-S) for people with advanced solid tumors, including ovarian, endometrial, lung, breast, and other cancers. The drug is designed to target and kill cancer cells, and the study aims to see if it is safe and effective.
Abilene, TexasAges 18 years+ - NCT07705035RecruitingPhase 1
DBC-664 for adults with advanced solid tumors
This trial tests a new drug called DBC-664 for people with solid tumors that have come back or spread and cannot be removed by surgery. It may be an option if you have tried other treatments or if standard options are limited.
San Antonio, TexasAges 18 years+ - NCT06293898RecruitingPhase 1
Study of BL-M07D1 for HER2-positive solid tumors
This trial tests a new drug, BL-M07D1, for people with advanced solid tumors that have a protein called HER2. It is for patients who have already tried at least two other standard treatments.
Fort Worth, TexasAges 18 years+ - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
Houston, TexasAges 18 years+ - NCT04429542RecruitingPhase 1
Test of an EGFR-targeting drug for advanced solid cancers
This Phase 1 study tests the safety of BCA101 (an EGFR-targeting treatment) alone or combined with pembrolizumab. It may help people with certain EGFR-driven advanced cancers, depending on the tumor type, prior treatments, and required biopsy testing.
Houston, TexasAges 18 years+
Recurrent Ovarian Carcinoma trials by city in Texas
Where these studies are running in Texas
Institutions with a site for the recruiting recurrent ovarian carcinoma studies listed above.
- The University of Texas MD Anderson Cancer Center · 14 studies
- NEXT Oncology · 4 studies
- START San Antonio · 4 studies
- University of Texas Health Science Center at San Antonio · 3 studies
- University of Texas Southwestern Medical Center · 3 studies
- Mary Crowley Cancer Research · 2 studies
- Oncology Consultants · 2 studies
- START Center for Clinical Research · 2 studies
What taking part in a recurrent ovarian carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Recurrent Ovarian Carcinoma trials in other states
Common questions
- Are there recurrent ovarian carcinoma clinical trials in Texas?
- Yes. We're currently tracking 36 recruiting recurrent ovarian carcinoma studies with a site in Texas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a recurrent ovarian carcinoma study in Texas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Texas to take part?
- Not necessarily. These studies have a site in Texas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a recurrent ovarian carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New recurrent ovarian carcinoma studies open in Texas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.